| 标题 |
Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1) |
| 网址 | |
| DOI |
10.1182/blood-2025-2123
doi
|
| 其它 |
期刊:Blood 作者:Constantine Tam; Andrzej Mital; Robert Weinkove; Wojciech Jurczak; Xin Yan; et al 出版日期:2025-12-05 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)